• +1-646-491-9876
    • +91-20-67278686

    Search

    Ischemia Reperfusion Injury-Pipeline Review H2 2017

    Ischemia Reperfusion Injury-Pipeline Review H2 2017

    • Report Code ID: RW0001881453
    • Category Life Sciences
    • No. of Pages 154
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Ischemia Reperfusion Injury-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury-Pipeline Review H2 2017 provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.

    Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache bradycardia seizures and hypertension. Risk factors include hypertension hyperlipidemia diabetes insulin resistance heart failure altered coronary circulation and aging.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase II Phase I IND/CTA Filed Preclinical and Discovery stages are 4 4 1 29 and 4 respectively. Similarly the Universities portfolio in Preclinical and Discovery stages comprises 21 and 4 molecules respectively.

    Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular) .
    - The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 4
    Ischemia Reperfusion Injury-Overview 5
    Ischemia Reperfusion Injury-Therapeutics Development 6
    Ischemia Reperfusion Injury-Therapeutics Assessment 20
    Ischemia Reperfusion Injury-Companies Involved in Therapeutics Development 30
    Ischemia Reperfusion Injury-Drug Profiles 40
    Ischemia Reperfusion Injury-Dormant Projects 142
    Ischemia Reperfusion Injury-Discontinued Products 145
    Ischemia Reperfusion Injury-Product Development Milestones 146
    Appendix 153

    List of Tables

    Number of Products under Development for Ischemia Reperfusion Injury H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Number of Products under Development by Companies H2 2017 (Contd..2) H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Number of Products under Development by Universities/Institutes H2 2017 (Contd..1) H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Products under Development by Companies H2 2017 (Contd..2) H2 2017
    Products under Development by Universities/Institutes H2 2017
    Products under Development by Universities/Institutes H2 2017 (Contd..1) H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Target H2 2017 (Contd..1) H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017 (Contd..1) H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Ischemia Reperfusion Injury-Pipeline by Angion Biomedica Corp H2 2017
    Ischemia Reperfusion Injury-Pipeline by Biomedica Management Corp H2 2017
    Ischemia Reperfusion Injury-Pipeline by Bolder Biotechnology Inc H2 2017
    Ischemia Reperfusion Injury-Pipeline by Catalyst Biosciences Inc H2 2017
    Ischemia Reperfusion Injury-Pipeline by Conatus Pharmaceuticals Inc H2 2017
    Ischemia Reperfusion Injury-Pipeline by Corline Biomedical AB H2 2017
    Ischemia Reperfusion Injury-Pipeline by Gilead Sciences Inc H2 2017
    Ischemia Reperfusion Injury-Pipeline by Glucox Biotech AB H2 2017
    Ischemia Reperfusion Injury-Pipeline by Hope Pharmaceuticals Inc H2 2017
    Ischemia Reperfusion Injury-Pipeline by Ischemix Inc H2 2017
    Ischemia Reperfusion Injury-Pipeline by Kowa Company Ltd H2 2017
    Ischemia Reperfusion Injury-Pipeline by NovelMed Therapeutics Inc H2 2017
    Ischemia Reperfusion Injury-Pipeline by Omeros Corp H2 2017
    Ischemia Reperfusion Injury-Pipeline by Opsona Therapeutics Ltd H2 2017
    Ischemia Reperfusion Injury-Pipeline by Orexo AB H2 2017
    Ischemia Reperfusion Injury-Pipeline by Pharming Group NV H2 2017
    Ischemia Reperfusion Injury-Pipeline by Prolong Pharmaceuticals LLC H2 2017
    Ischemia Reperfusion Injury-Pipeline by Prothix BV H2 2017
    Ischemia Reperfusion Injury-Pipeline by Reata Pharmaceuticals Inc H2 2017
    Ischemia Reperfusion Injury-Pipeline by Recordati SpA H2 2017
    Ischemia Reperfusion Injury-Pipeline by SBI Pharmaceuticals Co Ltd H2 2017
    Ischemia Reperfusion Injury-Dormant Projects H2 2017
    Ischemia Reperfusion Injury-Dormant Projects H2 2017 (Contd..1) H2 2017
    Ischemia Reperfusion Injury-Dormant Projects H2 2017 (Contd..2) H2 2017
    Ischemia Reperfusion Injury-Discontinued Products H2 2017

    List of Figures

    Number of Products under Development for Ischemia Reperfusion Injury H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Number of Products by Top 10 Targets H2 2017
    Number of Products by Stage and Top 10 Targets H2 2017
    Number of Products by Top 10 Mechanism of Actions H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Angion Biomedica Corp
    Biomedica Management Corp
    Bolder Biotechnology Inc
    Catalyst Biosciences Inc
    Conatus Pharmaceuticals Inc
    Corline Biomedical AB
    Gilead Sciences Inc
    Glucox Biotech AB
    Hope Pharmaceuticals Inc
    Ischemix Inc
    Kowa Company Ltd
    NovelMed Therapeutics Inc
    Omeros Corp
    Opsona Therapeutics Ltd
    Orexo AB
    Pharming Group NV
    Prolong Pharmaceuticals LLC
    Prothix BV
    Reata Pharmaceuticals Inc
    Recordati SpA
    SBI Pharmaceuticals Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//ischemia-reperfusion-injury-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//ischemia-reperfusion-injury-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//ischemia-reperfusion-injury-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments